t
GSK plc directors James Ford, Maya Martinez-Davis, and Shobie Ramakrishnan acquired American Depositary Shares (ADS) on October 13, 2026, on the New York Stock Exchange. These acquisitions, at a price of $46.9482 per ADS, followed the re-investment of dividends paid to shareholders on October 8, 2026. Mr. Ford acquired 326.441 ADS, Ms. Martinez-Davis acquired 351.842 ADS, and Ms. Ramakrishnan acquired 724.875 ADS.
| Date | 15 Oct 2026 |
| Time | 15:30:00 |
| Category | Director/PDMR dealings |
| ID | 1321Z |
GSK plc (the ‘Company’)
Transaction notification
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
James Ford | |||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS') ISIN: US37733W2044
| |||
|
b) |
Nature of the transaction |
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$46.9482 |
326.441
|
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-13 | |||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Maya Martinez-Davis | |||
|
b) |
Position/status |
President, US | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS') ISIN: US37733W2044
| |||
|
b) |
Nature of the transaction |
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$46.9482 |
351.842
|
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-13 | |||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Shobie Ramakrishnan | |||
|
b) |
Position/status |
Chief Digital and Technology Officer | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS') ISIN: US37733W2044
| |||
|
b) |
Nature of the transaction |
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$46.9482 |
724.875
|
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-13 | |||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) | |||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG